Qian Luo

Qian Luo

Auto-generated profile, based on publicly available information

Qian Luo

Department of Haematology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang, China

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 March 2023 in Cancer Medicine
Verified
Journal Article
Open access
WWWanchun Wu
Wanchun Wu
KRKexin Ren
Kexin Ren
XCXi Chen
Xi Chen
NLNa Li
Na Li
QLQian Luo
Qian Luo
LZLiqun Zhou
Liqun Zhou
Background: Nasal‐type extranodal natural killer (NK)/T cell lymphoma (ENKTL) is a rare and aggressive type of lymphoma. The optimal chemotherapy regimen for ENKTL has not yet been established. In this study, we compared the LVDP (L‐asparaginase, etoposide, dexamethasone, and cisplatin) and GLIDE (gemcitabine, L‐asparaginase, ifosfamide, dexamethasone, and etoposide) chemotherapy regimens for the treatment of ENKTL.Methods: A total of 267 patients with newly diagnosed ENKTL were included in this retrospective study. Propensity score matching (PSM) was used to adjust for confounders between the LVDP and GLIDE groups. Treatment responses, survival outcomes, and toxicities between the two groups were compared before and after PSM.Results: At the end of therapy, the objective response rate (ORR) and complete response (CR) were 83.5% and 62.2%, respectively, for all patients. The ORR and CR were 85.5% and 62.2% for the LVDP group compared with 79.3% and 62.2% for the GLIDE group, respectively, and no differences between the two groups were found (ORR, p = 0.212; CR, p = 0.996). With a median 71 months follow‐up, the 5‐year progression‐free survival (PFS) and overall survival (OS) rates were 64.3% and 68.5%, respectively. The 5‐year PFS and OS were 65.6% and 70.1% for the LVDP group compared with 61.6% and 64.6% for the GLIDE group, respectively (PFS, p = 0.478; OS, p = 0162). After PSM, no significant differences in short‐term efficacy (ORR, p = 0.696; CR, p = 0.264) or long‐term efficacy (PFS, p = 0.794; OS, p = 0.867) between the two groups were identified. However, treatment‐related toxicities were milder in the LVDP group compared to the GLIDE group, even after adjusting for confounders via PSM.Conclusion: In conclusion, both LVDP and GLIDE regimens are effective for the treatment of ENKTL. However, the LVDP regimen is safer than the GLIDE regimen, with milder treatment‐related toxicities. Therefore, the LVDP regimen could be a preferable option for patients with ENKTL.

1 October 2008
Verified
Conference Paper
Closed access
Taiyong LiTaiyong Li
Taiyong Li
CTChangjie Tang
Changjie Tang
JWJiang Wu
Jiang Wu
QLQian Luo
Qian Luo
SLShengzhi Li
Shengzhi Li
JZJie Zuo
Jie Zuo
Preservation of privacy in micro-data release is a challenging task in data mining. The k-anonymity method has attracted much attention of researchers. Quasi-identifier is a key concept in k-anonymity. The tuples whose quasi-identifiers have near effect on the sensitive attributes should be grouped to reduce information loss. The previous investigations ignored this point. This paper studies k-anonymity via clustering domain knowledge. The contributions include: (a) Constructing a weighted matrix based on domain knowledge and proposing measure methods. It carefully considers the effect between the quasi-identifiers and the sensitive attributes. (b) Developing a heuristic algorithm to achieve k-anonymity via clustering domain knowledge based on the measure methods. (c) Implementing the algorithm for privacy preservation, and (d) Experiments on real data demonstrate that the proposed k-anonymous methods decrease 30% information loss compared with basic k-anonymity.

1 April 2026 in Journal of Blood Medicine
Verified
Journal Article
Open access
PDF file
QLQian Luo
Qian Luo
XZXuzhao Zhang
Xuzhao Zhang
XQXi Qiu
Xi Qiu
HJHuawei Jiang
Huawei Jiang
YXYang Xu
Yang Xu
Teclistamab, a B-cell maturation antigen (BCMA) × CD3 bispecific T-cell engager, has shown significant efficacy in patients with refractory multiple myeloma (MM). However, the clinical characteristics and optimal management strategies for localized cytokine release syndrome (CRS) remain poorly defined compared with systemic CRS. We report the case of a 57-year-old woman with refractory MM who developed both systemic and localized CRS following teclistamab therapy. She initially presented with grade 3 systemic CRS during step-up dosing phase, which partially resolved with intravenous methylprednisolone. However, interleukin-6 remained elevated in pleural effusions but not in serum, indicating localized pleural cavity CRS. Management with pleural fluid drainage combined with intrapleural dexamethasone successfully controlled the localized CRS. At two months, the patient achieved a partial response and continued teclistamab therapy. To our knowledge, this is among the first reported cases of teclistamab-associated localized pleural cavity CRS effectively managed with intrapleural dexamethasone.

16 June 2026 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
HZHuijie Zhou
Huijie Zhou
QLQiuluo Liu
Qiuluo Liu
KRKexing Ren
Kexing Ren
QLQian Luo
Qian Luo
CYChunli Yang
Chunli Yang
LZLiqun Zhou
Liqun Zhou
Background Extranodal NK/T-cell lymphoma (ENKTL) is a rare, aggressive lymphoma in which radioresistance remains a major cause of treatment failure in the relapsed/refractory (R/R) setting. Methods We analysed XPO1 expression in ENKTL and assessed its role in radiosensitization using monoallelic XPO1-knockout models and KPT-330 in vitro and in xenografts. Mechanistic studies focused on the c-Myc–RAD51/CHEK1 axis, and clinical efficacy was evaluated in two R/R patients. Results Immunohistochemistry showed XPO1 overexpression in primary treatment-naïve ENKTL specimens relative to nasal polyp controls, and high XPO1 expression was associated with inferior overall survival. Monoallelic XPO1 knockout impaired homologous recombination (HR) repair, establishing a DNA repair defect exploitable as a radiosensitizing vulnerability. Pharmacologic inhibition of XPO1 with KPT-330 recapitulated these HR defects and synergised with radiotherapy. Mechanistically, KPT-330 disrupts the XPO1–c-Myc–RAD51/CHEK1 axis by blocking c-Myc nuclear export, reducing c-Myc abundance and promoter occupancy at the RAD51 and CHEK1 loci, thereby impairing HR. In two heavily pretreated R/R ENKTL patients, radiotherapy rechallenge plus low-dose KPT-330 achieved one partial response and one complete response with manageable toxicity. Conclusions XPO1 inhibition impairs HR and enhances radiosensitivity by disrupting the c-Myc–RAD51/CHEK1 axis. These findings support prospective evaluation of KPT-330–based radiosensitization in R/R ENKTL. The alternative text for this image may have been generated using AI.

28 November 2017 in Journal of Environmental Science and Engineering B
Verified
Journal Article
Open access
ZZZhou Zhi’eN
Zhou Zhi’eN
FWFang Weikai
Fang Weikai
LQLuo Qian
Luo Qian
WXWang Xiaochen
Wang Xiaochen
WLWu Liping
Wu Liping